• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

改善肿瘤乏氧环境及乏氧应激释药型抗肿瘤药纳米递送系统研究进展

梁金来, 徐巍, 殷婷婕, 霍美蓉

梁金来, 徐巍, 殷婷婕, 霍美蓉. 改善肿瘤乏氧环境及乏氧应激释药型抗肿瘤药纳米递送系统研究进展[J]. 中国药科大学学报, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301
引用本文: 梁金来, 徐巍, 殷婷婕, 霍美蓉. 改善肿瘤乏氧环境及乏氧应激释药型抗肿瘤药纳米递送系统研究进展[J]. 中国药科大学学报, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301
LIANG Jinlai, XU Wei, YIN Tingjie, HUO Meirong. Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve[J]. Journal of China Pharmaceutical University, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301
Citation: LIANG Jinlai, XU Wei, YIN Tingjie, HUO Meirong. Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve[J]. Journal of China Pharmaceutical University, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301

改善肿瘤乏氧环境及乏氧应激释药型抗肿瘤药纳米递送系统研究进展

基金项目: 国家自然科学基金资助项目(No.81703442,No.81102397,No.81503261)

Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

  • 摘要: 乏氧是多数实体肿瘤的特征之一,影响肿瘤的侵袭和转移,是抗肿瘤药产生耐药性的一个主要原因。基于高压氧或是血液代用品递送O2至肿瘤部位或是设计能催化肿瘤内源性H2O2分解产生O2的治疗方法,提高肿瘤组织中的含氧量,改善肿瘤乏氧环境,有助于肿瘤治疗。此外,基于肿瘤乏氧微环境设计乏氧应激释药型纳米递送体系,提高靶点药物浓度,提高药物疗效并降低其不良反应。本文主要从缓解肿瘤乏氧微环境以及肿瘤乏氧微环境响应型纳米靶向递药体系进行详细综述,为研究和开发新型抗肿瘤药提供方法学借鉴。
    Abstract: Hypoxia, a salient feature of solid tumors, is often associated with invasiveness, metastasis and resistance to anticancer drugs. The strategies including the use of oxygen-carriers based on hyperbaric oxygen and blood substitutes to transport oxygen into tumors or in situ generation of O2 from the tumor microenvironment endogenous H2O2 have been explored to relieve the tumor hypoxia and to improve therapeutic efficiency. In addition, it is potential to design hypoxia-responsive nanocarriers based on tumor hypoxia microenvironment to deliver anticancer drugs to the targeted tumor site, thereby improve drug concentrations in targeted site, significantly increase the antitumor efficiency and reduce the side-effects of drugs. This review gives an overview of the advances in relieving tumor hypoxia and hypoxia-responsive nanocarriers for tumor to provide a reference for the research and development of new antitumor drugs.
  • [1] Alimoradi H,Matikonda SS,Gamble AB,et al.Hypoxia responsive drug delivery systems in tumor therapy[J].Curr Pharm Des,2016,22(19):2808-2820.
    [2] Rapisarda A,Melillo G.Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies[J].Drug Resist Updat,2009,12(3):74-80.
    [3] Bryant JL,Meredith SL,Williams KJ,et al.Targeting hypoxia in the treatment of small cell lung cancer[J].Lung Cancer,2014,86(2):126-32.
    [4] Du J,Lane LA,Nie S.Stimuli-responsive nanoparticles for targeting the tumor microenvironment[J].J Control Release,2015,219:205-214.
    [5] Khawar IA,Kim JH,Kuh HJ.Improving drug delivery to solid tumors:priming the tumor microenvironment[J].J Control Release,2015,201:78-89.
    [6] Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer—a review[J].Target Oncol,2012,7(4):233-242.
    [7] Alam F,Yadav N,Ahmad M,et al.Blood substitutes:possibilities with nanotechnology[J].Indian J Hematol Blood Transfus,2014,30(3):155-162.
    [8] Spahn DR.Blood substitutes.Artificial oxygen carriers:perfluorocarbon emulsions[J].Crit Care,1999,3(5):R93-97.
    [9] Greenburg AG,Kim HW.Hemoglobin-based oxygen carriers[J].Crit Care,2004,8(Suppl 2):S61-S64.
    [10] Yuan J,Cen Y,Kong XJ,et al.MnO2-nanosheet-modified upconversion nanosystem for sensitive turn-on fluorescence detection of H2O2 and glucose in blood[J].ACS Appl Mater Interfaces,2015,7(19):10548-10555.
    [11] Fan W, Bu W, Shen B, et al. Intelligent MnO2 nanosheets anchored with upconversionnanoprobes for concurrent pH-/H2O2-responsive UCL imaging and oxygen-elevated synergetic therapy[J].Adv Mater,2015,27(28):4155-4161.
    [12] Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies,including brain tumours[J].Med Oncol,2016,33(9):101.
    [13] Peng HS,Liao MB,Zhang MY,et al.Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells[J].PLoS One,2014,9(6):e100814.
    [14] Lu Z, Ma J, Liu B, et al. Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice[J].Cancer Med,2016,5(11):3147-3155.
    [15] Hartmann KA,van der Kleij AJ,Carl UM,et al.Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H[J].Int J Radiat Oncol Biol Phys,2001,51(4):1037-1044.
    [16] Wu W,Yang Q,Li T,et al.Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors[J].Artif Cells Blood Substit Immobil Biotechnol,2009,37(4):163-165.
    [17] Vásquez DM,Ortiz D,Alvarez OA,et al.Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood[J].Biotechnol Prog,2013,29(3):796-807.
    [18] Riess JG.Perfluorocarbon-based oxygen delivery[J].Artif Cells Blood Substit Immobil Biotechnol,2006,34(6):567-580.
    [19] Li F,Mei H,Gao Y,et al.Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer[J].Biomaterials,2017,145:56-71.
    [20] Luo Z,Zheng M,Zhao P,et al.Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy[J].Sci Rep,2016,6:23393.
    [21] Cheng Y,Cheng H,Jiang C,et al.Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy[J].Nat Commun,2015,6:8785.
    [22] Song X,Feng L,Liang C,et al.Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies[J].Nano Lett,2016,16(10):6145-6153.
    [23] Zhang L,Li J,Zong L,et al.Reactive oxygen species and targeted therapy for pancreatic cancer[J].Oxid Med Cell Longev,2016,2016(3):1616781.
    [24] Vilema-Enríquez G,Arroyo A,Grijalva M,et al.Molecular and cellular effects of hydrogen peroxide on human lung cancer cells:potential therapeutic implications[J].Oxid Med Cell Longev,2016,2016(6):1-12.
    [25] Lennicke C,Rahn J,Lichtenfels R,et al.Hydrogen peroxide-production,fate and role in redox signaling of tumor cells[J].Cell Commun Signal,2015,13:39.
    [26] Chen Q, Chen J, Liang C, et al. Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration,hypoxia relieve,and synergistic combination therapy[J].J Control Release,2017,263:79-89.
    [27] Prasad P,Gordijo CR,Abbasi AZ,et al.Multifunctional albumin-MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia,acidosis,vascular endothelial growth factor and enhance radiation response[J].ACS Nano,2014,8(4):3202-3212.
    [28] Chen H,He W,Guo Z.An H2O2-responsive nanocarrier for dual-release of platinum anticancer drugs and O2:controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells[J].Chem Commun(Camb),2014,50(68):9714-9717.
    [29] Chen H,Tian J,He W,et al.H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells[J].J Am Chem Soc,2015,137(4):1539-1547.
    [30] Song G,Chen Y,Liang C,et al.Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy[J].Adv Mater,2016,28(33):7143-7148.
    [31] Zhu W,Dong Z,Fu T,et al.Modulation of hypoxia in solid tumor microenvironment with MnO2 nanoparticles to enhance photodynamic therapy[J].Adv Funct Mater,2016,26(30):5490-5498.
    [32] Gao S,Wang G,Qin Z,et al.Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy[J].Biomaterials,2017,112:324-335.
    [33] Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs[J].Cancer Chemother Pharmacol,2016,77(3):441-457.
    [34] Guise CP,Mowday AM,Ashoorzadeh A,et al.Bioreductive prodrugs as cancer therapeutics:targeting tumor hypoxia[J].Chin J Cancer,2014,33(2):80-86.
    [35] Denny WA.Hypoxia-activated prodrugs in cancer therapy:progress to the clinic[J].Future Oncol,2010,6(3):419-428.
    [36] Denny WA,Wilson WR,Hay MP.Recent developments in the design of bioreductive drugs[J].Br J Cancer Suppl,1996,27:S32-S38.
    [37] Mistry IN, Thomas M, Calder EDD, et al. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy[J].Int J Radiat OncolBiol Phys,2017,98(5):1183-1196.
    [38] Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy[J].ACS Nano,2017,11(1):927-937.
    [39] Li SY, Cheng H, Qiu WX, et al. Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy[J].Biomaterials,2017,142:149-161.
    [40] Wang Y,Xie Y,Li J,et al.Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy[J].ACS Nano,2017,11(2):2227-2238.
    [41] Thambi T,Park JH,Lee DS.Hypoxia-responsive nanocarriers for cancer imaging and therapy:recent approaches and future perspectives[J].Chem Commun(Camb),2016,52(55):8492-8500.
    [42] Thambi T,Deepagan VG,Yoon HY,et al.Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery[J].Biomaterials,2014,35(5):1735-1743.
    [43] Kang L,Fan B,Sun P,et al.An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome[J].Acta Biomater,2016,44:341-354.
    [44] Ahmad Z,Lv S,Tang Z,et al.Methoxy poly(ethylene glycol)-block-poly(glutamic acid)-graft-6-(2-nitroimidazole)hexyl amine nanoparticles for potential hypoxia-responsive delivery of doxorubicin[J].J Biomater Sci Polym Ed,2016,27(1):40-54.
    [45] Liu H,Zhang R,Niu Y,et al.Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy[J].RSC Adv,2015,5(27):20848-20857.
    [46] Perche F,Biswas S,Wang T,et al.Hypoxia-targeted siRNA delivery[J].Angew Chem Int Ed Engl,2014,53(13):3362-3366.
    [47] Kulkarni P,Haldar MK,You S,et al.Hypoxia-responsive polymersomes for drug delivery to hypoxic pancreatic cancer cells[J].Biomacromolecules,2016,17(8):2507-2513.
计量
  • 文章访问数:  1477
  • HTML全文浏览量:  9
  • PDF下载量:  4467
  • 被引次数: 0
出版历程
  • 刊出日期:  2018-06-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭